H1.co alternative · for precision-oncology biotech medical affairs
H1 alternative for precision-oncology medical affairs: gene- and indication-level KOL ranking
UNMIRI · See Literature Intelligence
H1's HCP Universe is a strong all-therapeutic-area KOL platform. Publications, trials, conference activity, $73B in payments data, social/digital footprint. The breadth is real. For biopharma running diverse therapeutic-area portfolios, H1 has the coverage.
UNMIRI Engine 3 is built for the slice H1 can't economically deepen: gene- and indication-level KOL ranking for precision-oncology medical affairs.A medical affairs team launching an EGFR drug in NSCLC needs oncologists ranked by that gene and tumor type, not by overall oncology publication volume. H1 can't do this without bolting on a genomic ontology they don't own. UNMIRI joins literature signal to the gene-and-indication graph from Engines 1 and 2, so the KOL ranking is conditioned on gene and tumor type by design.
At a glance
| Dimension | H1.co | UNMIRI |
|---|---|---|
| Scope | All therapy areas: oncology, rare disease, cardiology, neuro, etc. | Oncology-only, gene- and indication-stratified |
| KOL ranking signal | Aggregate publication volume, trial activity, payments, social engagement | Gene- and indication-conditioned: ranks KOLs by recent publications on a specific gene + tumor-type pair |
| Buyer | Mid-to-large biopharma medical affairs, clinical operations, commercial analytics | 50-500 employee oncology biotech medical affairs |
| Pricing | Mid-five to low-seven figures annually, multi-year enterprise contracts | $149/mo individual, $599/mo team, enterprise custom (unlimited, SSO, BAA) |
| Deployment time | Enterprise procurement: months to onboarding | Self-serve PLG: 14-day trial, no credit card, deployable in days |
| Output formats | H1 UI, AI-Powered Interactions for pre-call planning, Salesforce/Veeva integrations | Daily/weekly digest, KOL profiles, competitive landscape PDF, watchlist alerts, markdown/docx export, API |
Gene- and indication-conditioned ranking is the whole point
Take a concrete example: a medical affairs team launching a KRAS inhibitor in NSCLC needs to know which oncologists are publishing on KRAS in NSCLC, not which oncologists are publishing on lung cancer generally. H1 ranks the latter. UNMIRI ranks the former because the literature signal is joined to UNMIRI's gene-and-indication graph, the same Neo4j knowledge graph that powers Engines 1 and 2.
The other H1 wedge is buying motion. H1 is enterprise sales, contract negotiation, integration with Veeva or Salesforce. UNMIRI Engine 3 is PLG: trial, decide, expand. For a biotech that doesn't have enterprise procurement bandwidth and doesn't want to wait two quarters, that's the deciding factor.
When H1.co is the right pick
- You're running multi-therapeutic-area medical affairs and need one platform across oncology + rare disease + cardiology + neuro.
- You're standardized on Veeva CRM and want deep native integration into your pre-call planning workflow (UNMIRI ships Salesforce today, Veeva on request).
- Your team is mid-to-large biopharma with enterprise-procurement budget and time for a months-long deployment.
- You need payments / engagement data depth for HCP relationship management beyond literature.
When UNMIRI is the right pick
- You're at a precision-oncology biotech (50-500 employees) where every KOL recommendation needs to be specific to your drug's gene and tumor type.
- Your team is six to twenty MSLs, not a hundred. Enterprise procurement isn't a fit; PLG self-serve is.
- Gene- and indication-level ranking is the actual deliverable. "Top-10 oncology KOLs by recent publications on KRAS in NSCLC" is the daily query, not "top oncology KOLs."
- You want to evaluate it Tuesday, not negotiate it for two quarters.
- Your MLR review process favors deterministic-template output over multi-source aggregated scoring.
Frequently asked questions
- Does UNMIRI cover non-oncology therapeutic areas?
- No. UNMIRI is oncology-only by design. The gene-and-indication graph is oncology-specific. If you need rare disease, immunology, cardiology, or neuro KOL coverage, H1 is the right tool and UNMIRI isn't in the running.
- Can we run UNMIRI alongside an existing H1 subscription?
- Yes. Many do during evaluation. There's no exclusivity. UNMIRI handles the gene- and indication-level oncology KOL slice; you keep H1 for everything outside oncology or for workflows that don't need gene- and indication-level ranking.
- How does the gene- and indication-level ranking actually work?
- The relevance score and KOL ranking incorporate gene- and indication-level signal from the Neo4j knowledge graph. When you set a watchlist with "KRAS + NSCLC," the KOL feed surfaces oncologists who have authored on that gene + tumor-type pair recently, ranked by publication recency, citation density, and congress activity tied to that gene and indication, not by aggregate oncology publication volume. Variant-level KOL ranking is not a current capability.
- What about Salesforce / Veeva integration?
- Salesforce integration is live now, with Veeva available on request. If a deep, native Veeva workflow is non-negotiable, H1 is still the more mature fit today; but if you want KOL profiles, pre-call packs, and watchlist signal flowing into Salesforce, UNMIRI ships that.
Try the gene- and indication-level feed
14-day trial, no credit card. Set your watchlist to your drug + biomarker + competitive set, and see how gene- and indication-conditioned ranking differs from generic KOL discovery.